{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:02:16Z","timestamp":1774551736001,"version":"3.50.1"},"reference-count":44,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.5551\/jat.57265","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T22:06:46Z","timestamp":1599516406000},"page":"873-882","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention"],"prefix":"10.5551","volume":"28","author":[{"given":"Jianan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yida","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubin","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuejin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runlin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Paarup Dridi N, Johansson PI, L\u00f8nborg JT, Clemmensen P, Radu MD, Qayyum A, Pedersen F, Kollslid R, Helqvist S, Saunam\u00e4ki K, Kelb\u00e6k H, J\u00f8rgensen E, Engstr\u00f8m T, Holmvang L. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. Platelets, 2015; 26: 521-529","DOI":"10.3109\/09537104.2014.948837"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133: 199S-233S","DOI":"10.1378\/chest.08-0672"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J, 2009; 30: 426-435","DOI":"10.1093\/eurheartj\/ehn562"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, B\u00fcttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol, 2006; 48: 1742-1750","DOI":"10.1016\/j.jacc.2006.06.065"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Sch\u00f6mig A, Kastrati A, von Beckerath N. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost, 2010; 103: 151-159","DOI":"10.1160\/TH09-05-0284"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Clemmensen P, Dridi NP, Holmvang L. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Cardiovasc Drugs Ther, 2013; 27: 239-245","DOI":"10.1007\/s10557-013-6444-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thors\u00e9n M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009; 361: 1045-1057","DOI":"10.1056\/NEJMoa0904327"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol, 2012; 25: 348-356","DOI":"10.1021\/tx2004085"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemst, 2009; 7: 1556-1565","DOI":"10.1111\/j.1538-7836.2009.03527.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet, 2010; 375: 283-293","DOI":"10.1016\/S0140-6736(09)62191-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kang J, Han JK, Ahn Y, Chae SC, Kim YJ, Chae IH, Hur SH, Seong IW, Chae JK, Cho MC, Seung KB, Jeong MH, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS; investigators for Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH). Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study. Thromb Haemost, 2018; 118: 591-600","DOI":"10.1055\/s-0038-1626697"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B, Schulte PJ, Storey RF, Wallentin L, Gabriel Steg P, James SK; PLATO Investigators. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart, 2016; 102: 617-625","DOI":"10.1136\/heartjnl-2015-308963"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sim DS, Jeong MH, Kim HS, Gwon HC, Seung KB, Rha SW, Chae SC, Kim CJ, Cha KS, Park JS, Yoon JH, Chae JK, Joo SJ, Choi DJ, Hur SH, Seong IW, Cho MC, Kim DI, Oh SK, Ahn TH, Hwang JY; KAMIR-NIH Registry Investigators. Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction. J Cardiol, 2019; 73: 142-150","DOI":"10.1016\/j.jjcc.2018.09.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Pollack CV Jr, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L, Cannon CP; PLATO Investigators. Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol, 2017; 40: 390-398","DOI":"10.1002\/clc.22733"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kristian Thygesen, Joseph S Alpert, Harvey D White, Joint ESC\/ACCF\/AHA\/WHF Task Force for the Redefinition of Myocardial Infarction. Universal Definition of Myocardial Infarction. Eur Heart J, 2007; 28: 2525-2538","DOI":"10.1093\/eurheartj\/ehm355"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation, 2007; 115: 2344-2351","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol, 1988; 11: 1-11","DOI":"10.1016\/0735-1097(88)90158-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J, 2009; 157: 599-605","DOI":"10.1016\/j.ahj.2009.01.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tapp L, Shantsila E, Lip GY. Role of ticagrelor in clopidogrel nonresponders: resistance is futile? Circulation, 2010; 121: 1169-1171","DOI":"10.1161\/CIR.0b013e3181d8d929"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bj\u00f6rkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther, 2012; 17: 164-172","DOI":"10.1177\/1074248411410883"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation, 2009; 120: 2577-2585","DOI":"10.1161\/CIRCULATIONAHA.109.912550"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Gurbel PA, Bliden KP, Antonino M, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation, 2010; 121: 1188-1199","DOI":"10.1161\/CIRCULATIONAHA.109.919456"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Husted SE, Storey RF, Bliden K, Tantry US, H\u00f8imark L, Butler K, Wei C, Teng R, Gurbel PA. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet, 2012; 51: 397-409","DOI":"10.2165\/11599830-000000000-00000"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Price MJ, Clavijo L, Angiolillo DJ, Carlson G, Caplan R, Teng R, Maya J. A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. J Thromb Thrombolysis, 2015; 39: 8-14","DOI":"10.1007\/s11239-014-1135-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Li H, Guo J, Carlson GF, Teng R. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Br J Clin Pharmacol, 2016; 82: 352-361","DOI":"10.1111\/bcp.12950"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) He M, Liu B, Sun D, Pan Y, Zheng W, Shi J, Zhao S, Dong X, Lu S, Li M, Han Y, Li Y. One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. Int J Cardiol, 2016; 215: 209-213","DOI":"10.1016\/j.ijcard.2016.04.087"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) \u00c5strand M, Amilon C, R\u00f6shammar D, Himmelmann A, Angiolillo DJ, Storey RF, Gurbel PA, Bonaca MP, Hamr\u00e9n B. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol, 2019; 85: 413-421","DOI":"10.1111\/bcp.13812"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Keun-Ho Park, Myung Ho Jeong, Youngkeun Ahn, Tae Hoon Ahn, Ki Bae Seung, Dong Joo Oh, Dong-Joo Choi, Hyo-Soo Kim, Hyeon Cheol Gwon, In Whan Seong, Kyung Kuk Hwang, Shung Chull Chae, Kwon-Bae Kim, Young Jo Kim, Kwang Soo Cha, Seok Kyu Oh, Jei Keon Chae, KAMIR-NIH registry investigators. Comparison of Short-Term Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Patients With Acute Myocardial Infarction Undergoing Successful Revascularization; From Korea Acute Myocardial Infarction Registry-National Institute of Health. Int J Cardiol, 2016; 215: 193-200","DOI":"10.1016\/j.ijcard.2016.04.044"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Anders Sahl\u00e9n, Christoph Varenhorst, Bo Lagerqvist, Henrik Renlund, Elmir Omerovic, David Erlinge, Lars Wallentin, Stefan K James, Tomas Jernberg. Outcomes in Patients Treated With Ticagrelor or Clopidogrel After Acute Myocardial Infarction: Experiences From SWEDEHEART Registry. Eur Heart J, 2016; 37: 3335-3342","DOI":"10.1093\/eurheartj\/ehw284"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. Circ J, 2015; 79: 2452-2460","DOI":"10.1253\/circj.CJ-15-0112"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Jeong Cheon Choe, Kwang Soo Cha, Jinhee Ahn, Jin Sup Park, Hye Won Lee, Jun-Hyok Oh, Jung Hyun Choi, Han Cheol Lee, Taek Jong Hong, Myung Ho Jeong, Korea Acute Myocardial Infarction Registry\u2013National Institutes of Health Investigators. Comparison of Prescription Rates and Clinical Outcomes in Acute Coronary Syndrome Patients Who Underwent Percutaneous Coronary Intervention Using Different P2Y 12 Inhibitors in a Large Observational Study. Int J Cardiol, 2019; 274: 21-26","DOI":"10.1016\/j.ijcard.2018.09.011"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Hyun-Jae Kang, Robert M Clare, Runlin Gao, Claes Held, Anders Himmelmann, Stefan K James, Soo Teik Lim, Anwar Santoso, Cheuk-Man Yu, Lars Wallentin, Richard C Becker, PLATO Investigators. Ticagrelor Versus Clopidogrel in Asian Patients With Acute Coronary Syndrome: A Retrospective Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J, 2015; 169: 899-905","DOI":"10.1016\/j.ahj.2015.03.015"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Jessica Ristorto, Nathan Messas, Benjamin Marchandot, Marion Kibler, S\u00e9bastien Hess, Nicolas Meyer, Michael Schaeffer, Nicolas Tuzin, Patrick Ohlmann, Laurence Jesel, Olivier Morel. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors. J Atheroscler Thromb, 2018; 25: 674-689","DOI":"10.5551\/jat.40584"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Xiuying Tang, Runjun Li, Quanmin Jing, Qingsheng Wang, Peng Liu, Peidong Zhang, Yingfeng Liu. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Cardiovasc Pharmacol, 2016; 68: 115-120","DOI":"10.1097\/FJC.0000000000000390"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC Jr. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol, 2014; 11: 597-606","DOI":"10.1038\/nrcardio.2014.104"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, Noh GJ, Njau R, Close S, Wise S, Hockett R. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010; 50: 929-940","DOI":"10.1177\/0091270009355161"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Wells RS, Yuldasheva N, Ruzibakiev R, Underhill PA, Evseeva I, Blue-Smith J, Jin L, Su B, Pitchappan R, Shanmugalakshmi S, Balakrishnan K, Read M, Pearson NM, Zerjal T, Webster MT, Zholoshvili I, Jamarjashvili E, Gambarov S, Nikbin B, Dostiev A, Aknazarov O, Zalloua P, Tsoy I, Kitaev M, Mirrakhimov M, Chariev A, Bodmer WF. The Eurasian heartland: a continental perspective on Y-chromosome diversity. Proc Natl Acad Sci U S A, 2001; 98: 10244-10249","DOI":"10.1073\/pnas.171305098"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, J\u00fcni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018; 39: 213-260","DOI":"10.1016\/j.rec.2017.11.020"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Montalescot G, Sechtem U, Achenbach S, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabat\u00e9 M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryd\u00e9n L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J, 2013; 34: 2949-3003","DOI":"10.1093\/eurheartj\/eht296"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Nusca A, Patti G, Di Sciascio G. Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. J Cardiovasc Transl Res, 2013; 6: 346-354","DOI":"10.1007\/s12265-012-9439-7"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Piqueras-Flores J, Jurado-Rom\u00e1n A, L\u00f3pez-Lluva MT, S\u00e1nchez-P\u00e9rez I, Abell\u00e1n-Huerta J, Lozano-Ruiz Poveda F. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention. J Cardiovasc Pharmacol, 2019; 73: 56-59","DOI":"10.1097\/FJC.0000000000000632"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J, 2020; 41: 407-477","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O\u2019Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2016; 68: 1082-1115","DOI":"10.1016\/j.jacc.2016.03.513"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Masato Nakamura, Kazuo Kimura, Takeshi Kimura, Masaharu Ishihara, Fumiyuki Otsuka, Ken Kozuma, Masami Kosuge, Toshiro Shinke, Yoshihisa Nakagawa, Masahiro Natsuaki, Satoshi Yasuda, Takashi Akasaka, Shun Kohsaka, Kazuo Haze, Atsushi Hirayama. JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. Circ J, 2020; 84: 831-865","DOI":"10.1253\/circj.CJ-19-1109"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/8\/28_57265\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T04:01:55Z","timestamp":1628308915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/8\/28_57265\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.57265","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,1]]},"article-number":"57265"}}